Celiprolol

In the field of cardiovascular diseases, β-blockers are a core category of medications for the chronic disease management of hypertension, coronary heart disease and other conditions. The third-generation β-blockers, while retaining the antihypertensive effect, have both α1 receptor blocking effect and intrinsic sympathomimetic activity, which can reduce the negative impacts of traditional β-blockers on lipid and blood glucose metabolism. Celiprolol is exactly the representative of such highly selective preparations. It can competitively block β1 receptors and mildly dilate peripheral blood vessels, and is indicated for the treatment of mild to moderate essential hypertension. It can also be safely used in patients with concomitant coronary heart disease and chronic stable angina pectoris, and is particularly suitable for middle-aged and elderly hypertensive populations at risk of metabolic abnormalities, as it can control blood pressure while reducing the incidence of adverse reactions.

The global celiprolol market size reached approximately USD 120 million in 2023. In recent years, with the rising prevalence of hypertension and the increasing clinical recognition of highly selective β-blockers, the annual compound growth rate of the market has remained at around 3.8%. At present, the market is dominated by generic drug supplies, with Europe and India being the main API production regions. There are no domestic enterprises with large-scale mass production yet, and clinical medications are still dominated by imported preparations and a small number of generic drugs processed from imported APIs, with relatively high costs. Celiprolol has not been included in the national centralized procurement scope, and there is a large substitution space in the market supply.

The original research enterprise of celiprolol is Sanofi, France, with the original brand name Celectol, and its core compound patent expired globally in 2003. The main dosage form approved for the original drug is tablet, with two specifications of 100mg and 200mg. This original preparation has been included in the FDA Reference Listed Drug Catalog, and has not been included in the Chinese *Catalog of Reference Preparations for Chemical Drugs* yet. There is no approved celiprolol registration number with A status on the domestic API registration platform, and all celiprolol preparations approved for marketing are imported varieties. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for celiprolol API, which can cover the reference substance requirements in the whole process of API R&D, quality research and registration declaration. Most products are available from stock, and spot orders placed before 16:00 can be shipped on the same day. The products meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference material support for the R&D and production links of relevant enterprises.